Use of the oxytocin receptor blocking agent atosiban to suppress spontaneous labor


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Suppression of spontaneous contractile activity in the uterus in preterm pregnancy increases the chances of neonatal survival. Oxytocin induces uterine contractions, thus suppression of its activity is the major aim of premature labor. Atosiban is the first agent specially designed to suppress labor. Its mechanism of action is via inhibition of oxytocin receptors. Its comparison with other agents having tocolytic activity shows that atosiban is as effective as the tocolytics and surpasses them in safety and tolerability in the treatment of pregnant women with threatened premature labor, which can recommend it as first-line agent for this group of women.

Full Text

Restricted Access

About the authors

O. R Baev

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: metod_obsgyn@hotmail.com
MD, the Head of Maternity Department

O. A Kozlova

I.M. Sechenov First MSMU, Ministry of Health of Russia

Email: olgandrevna@mail.ru
Postgraduate student, Department of Obstetrics, Gynecology, Reproduction and Perinatology, Faculty for Postgraduate Medical Education

O. V Tysyachnyi

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: olti23@mail.ru
Postgraduate student

E. A Usova

Academician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: bipunctata@rambler.ru
Postgraduate student

References

  1. Usta I.M., Khalil A., Nassar A.H. Oxytocin antagonists for the management of preterm birth: a review. Am. J. Perinatol. 2011; 28(6): 449-60. doi: 10.1055/s-0030-1270111.
  2. Сидельникова В.М. Преждевременные роды - современный взгляд на проблему. Вопросы практической педиатрии. 2006; 1(4): 55-6. [Sidelnikova V.M. Preterm birth - a modern approach to the problem. Questions of Practical Pediatrics. 2006; 1 (4): 55-6. (in Russian)]
  3. Lawn J.E., Gravett M.G., Nunes T.M., Rubens C.E., Stanton C.; GAPPS Review Group. Global report on preterm birth and stillbirth (1 of 7): defi nitions, description of the burden and opportunities to improve data. BMC Pregnancy Childbirth. 2010; 10(Suppl. 1): S1-22. Available at: http://www. biomedcentral.com/1471-2393/10/S1/S1
  4. Wood N., Marlow N., Costeloe K., Chir B., Gibson A., Wilkinson A. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N. Engl. J. Med. 2000; 343: 378-84.
  5. Finnstrom O., Olaussen P.O., Sedin G., Serenius F., Svenningsen N., Thiringer K. et al. The Swedish national perspectives study on extremely low birthweight (ELBW) infants. Incidence, mortality, morbidity and survival in relation to level of care. Acta Paediatr. 1997; 86: 503-11.
  6. Arthur P., Taggart M.J., Mitchell B.F. Oxytocin and parturition: a role for increased myometrial calcium and calcium sensitization? Front. Biosci. 2007; 12: 619-33.
  7. Vrachnis N., Malamas F.M., Sifakis S., Deligeoroglou E., Iliodromiti Z. The oxytocin-oxytocin receptor system and its antagonists as tocolytic agents. Int. J. Endocrinol. 2011; 2011: Article ID 350546. doi: 10.1155/2011/350546.
  8. Woodcock N., Taylor C., Thornton S. Effect of oxytocin receptor antagonist and rho kinase inhibitor on the Ca++ sensitivity of human myometrium. Am. J. Obstet. Gynecol. 2004; 190: 222-8.
  9. Fuchs A.R., Husslein P., Fuchs F. Oxytocin and the initiation of human parturition. II. Stimulation of prostaglandin production in human decidua by oxytocin. Am. J. Obstet. Gynecol. 1981; 141(6): 694-7.
  10. Серов В.Н., Салов И.А., Бурлев В.А., Маринушкин Д.Н. Роль фетального окситоцина в индукции сократительной деятельности матки. Российский вестник акушера-гинеколога. 2001; 1: 15-8. [Serov V.N., Salov I.A., Burlev V.A., Marinushkin D.N. Role of fetal oxytocin in inducing uterine activity. Russian Bulletin of obstetrician-gynecologist. 2001; 1: 15-8. (in Russian)]
  11. Baskett T.F. The development of oxytocic drugs in the management of postpartum haemorrhage. Ulster Med. J. 2004; Suppl.: 2-6.
  12. Du Vigneaud V., Ressler C., Trippett S. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J. Biol. Chem. 1953; 205: 949-57.
  13. Melin P., Trojnar J., Vilhardt H., Akerlund M. Uterotonic oxytocin and vasopressin antagonists with minimal structure modifications. In: Hruby V.J., Rich D.H., eds. Peptides: structure and function: Proceedings of the 8th American Peptide Symposium. Rockford, USA: Pierce Chemical; 1983: 361- 5.
  14. Melin P., Trojnar J., Johansson B., Vilhardt H., Akerlund M. Synthetic antagonists of the myometrial response to vasopressin and oxytocin. J. Endocrinol. 1986; 111(1): 125-31.
  15. Akerlund M., Carlsson A.M., Melin P., Trojnar J. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin. Acta Obstet. Gynecol. Scand. 1985; 64: 499-504.
  16. Akerlund M. Oxytocin antagonists in the treatment of preterm labour. Fetal Maternal Med. Rev. 2002; 13: 31-41.
  17. Lamont R.F., Greenfield P. Anti-oxytocic tocolytic agents. In: Srurdee D., Olah K., Purdie D., Keane D., eds. Yearbook of the Royal College of Obstetricians and Gynaecologists. London: RCOG Press; 2002; vol.10: 130-40.
  18. Lamont R.F., Kam K.Y.R. Atosiban as a tocolytics for the treatment of spontaneous preterm labor. Expert Rev. Obstet. Gynecol. 2008; 3(2): 163-74.
  19. Nanetti L., Raffaelli F., Giulietti A., Sforza G., Raffaele Giannubilo S., Ciavattini A. et al. Oxytocin, its antagonist atosiban, and preterm labor: a role for placental nitric oxide. J. Matern. Fetal Neonatal Med. 2014 Jul 11: 1-6.
  20. Valenzuela G.J., Craig J., Bernhardt M.D., Holland M.I. Placental passage of the oxytocin antagonist atosiban. Am. J. Obstet. Gynecol. 1995; 172(4, Pt 1): 1304-6.
  21. Greig P.C., Massmann G.A., Demarest K.T., Weglein R.C., Holland M.L., Figueroa J.P. Maternal and fetal cardiovascular effects and placental transfer of the oxytocin antagonist atosiban in late gestation pregnant sheep. Am. J. Obstet. Gynecol. 1993; 169(4): 897-902.
  22. Goodwin T.M., Valenzuela G., Silver H., Hayashi R., Creasy G.W., Lane R. Treatment of preterm labor with the oxytocin antagonist atosiban. Am. J. Perinatol. 1996; 13(3): 143-6.
  23. Romero R., Sibai B.M., Sanchez-Ramos L., Valenzuela G.J., Veille J.-C., Tabor B. et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue. Am. J. Obstet. Gynecol. 2000; 182: 1173-83.
  24. Helmer H., Brunbauer M., Rohrmeister K. Exploring the role of Tractocile in everyday clinical practice. Br. J. Obstet. Gynaecol. 2003; 110 (Suppl. 20): 113-5.
  25. Husslein P., Roura L., Dudenhausen J., Helmer H., Frydman R., Rizzo N., Schneider D. on behalf of the TREASURE study group. Clinical practice evaluation of atosiban in preterm labour management in six European countries. Br. J. Obstet. Gynaecol. 2006; 113(Suppl. 3): 105-10.
  26. Wu M.Y., Chen S.U., Lee C.N., Ho H.N., Yang Y.S. Use of atosiban in a twin pregnancy with extremely preterm premature rupture in the membrane of one twin: a case report and literature review. Taiwan J. Obstet. Gynecol. 2010; 49(4): 495-9. doi: 10.1016/S1028-4559(10)60103-9.
  27. Hadar E., Melamed N., Aviram A., Raban O., Saltzer L., Hiersch L., Yogev Y. Effect of an oxytocin receptor antagonist (atosiban) on uterine electrical activity. Am. J. Obstet. Gynecol. 2013; 209(4): 384. e1-7. doi: 10.1016/j. ajog.2013.05.053.
  28. Rasmussen B.B., Larsen L.S., Senderovitz Th. Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers. Br. J. Obstet. Gynaecol. 2005; 112: 1492-9.
  29. Sanu O., Lamont R.F. Critical appraisal and clinical utility of atosiban in the management of preterm labor. Ther. Clin. Risk Manag. 2010; 6: 191-9.
  30. Driul L., Londero A.P., Adorati-Menegato A., Vogrig E., Bertozzi S., Fachechi G. et al. Therapy side-effects and predictive factors for preterm delivery in patients undergoing tocolysis with atosiban or ritodrine for threatened preterm labour. J. Obstet. Gynaecol. 2014; Jun 24: 1-6.
  31. Shim J., Park Y., Yoon B., Cho Y., Yang J., Lee Y., Kim A. Multicentre, parallel group, randomised, single-blind study of the safety and efficacy of atosiban versus ritodrine in the treatment of acute preterm labour in Korean women. Br. J. Obstet. Gynaecol. 2006; 113: 1228-34.
  32. Cabar F.R., Bittar R.E., Gomes C.M., Zugaib M. Atosiban as a tocolytic agent: a new proposal of a therapeutic approach. Rev. Bras. Ginecol. Obstet. 2008; 30(2): 87-92.
  33. De Heus R., Mulder E.J., Visser G.H. Management of preterm labor: atosiban or nifedipine? Int. J. Women’s Health. 2010; 2: 137-42.
  34. Deshpande R., Thornton J. Atosiban clinical experience - efficacy and safety. Eur. Obstet. Gynaecol. 2009; 4(1): 46-9.
  35. Kashanian M., Akbarian A.R., Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor. Int. J. Gynaecol. Obstet. 2005; 91(1): 10-4.
  36. Saleh S.S., Al-Ramahi M.Q., Al Kazaleh F.A. Atosiban and nifedipine in the suppression of preterm labour: a comparative study. J. Obstet. Gynaecol. 2013; 33(1): 43-5. doi: 10.3109/01443615.2012.721822.
  37. Salim R., Garmi G., Nachum Z., Zafran N., Baram S., Shalev E. Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstet. Gynecol. 2012; 120(6): 1323-31. doi: http://10.1097/ AOG.0b013e3182755dff.
  38. Al-Omari W.R., Al-Shammaa H.B., Al-Tikriti E.M., Ahmed K.W. Atosiban and nifedipine in acute tocolysis: a comparative study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006; 128(1-2): 129-34.
  39. Hadar E., Mansur N., Ambar I., Hod M. Atosiban treatment for preterm labor--financial considerations and savings by implementing clinical guidelines. Harefuah. 2011; 150(6): 502-6, 553.
  40. Flenady V., Reinebrant H.E., Liley H.G., Tambimuttu E.G., Papatsonis D.N.M. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst. Rev. 2014; (6): CD004452. doi: 10.1002/14651858. CD004452.pub3.
  41. De Heus R., Mol B.W., Erwich J.J., van Geijn H.P., Gyselaers W.J., Hanssens M. et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. Br. Med. J. 2009; 338: b744. doi: 10.1136/bmj.b744.
  42. Venulet J., Bankowski Z Harmonising adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences. Drug Saf. 1998; 19(3): 165-72.
  43. Haas D.M., Caldwel D.M., Kirkpatrick P., McIntosh J.J., Welton N.J. Tocolytic therapy for preterm delivery: systematic review and network metaanalysis. Br. Med. J. 2012; 345: e6226. doi: 10.1136/bmj.e6226.
  44. Dodd J.M., Crowther C.A., Dare M.R., Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst. Rev. 2006; (1): CD003927.
  45. Han S., Crowther C.A., Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst. Rev. 2010; (7): CD000940. doi: 10.1002/14651858.CD000940.pub2.
  46. Naik Gaunekar N., Raman P., Bain E., Crowther C.A. Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour. Cochrane Database Syst. Rev. 2013; (10): CD004071. doi: 10.1002/14651858.CD004071.pub3.
  47. Valenzuela G.J., Sanchez-Ramos L., Romero R., Silver H.M. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am. J. Obstet. Gynecol. 2000; 182(5): 1184-90.
  48. Papatsonis D.N.M., Flenady V., Liley H.G. Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour. Cochrane Database Syst. Rev. 2013; (10): CD005938. doi: 10.1002/14651858. CD005938.pub3.
  49. Wex J., Connolly M., Rath W. Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation. BMC Pregnancy Childbirth. 2009; 9: 23. doi: 10.1186/1471-2393-9-23.
  50. Wex J., Abou-Setta A.M., Clerici G., Di Renzo G.C. Atosiban versus betamimetics in the treatment of preterm labour in Italy: clinical and economic importance of side-effects. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157(2): 128-35. doi: 10.1016/j.ejogrb.2011.04.009.
  51. Jorgensen J.S., Weile L.K., Lamont R.F. Preterm labor: current tocolytic options for the treatment of preterm labor. Expert Opin. Pharmacother. 2014; 15(5): 585-8.
  52. Kam K.Y., Lamont R.F. Developments in the pharmacotherapeutic management of spontaneous preterm labor. Expert Opin. Pharmacother. 2008; 9(7): 1153-68. doi: 10.1517/14656566.9.7.1153.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies